Published on in Vol 9, No 7 (2021): July
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/29226, first published
.
Journals
- Zhong T, Fan Y, Dong X, Guo X, Wong K, Wong W, He D, Liu S. An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis. Frontiers in Pharmacology 2021;12 View
- Chen L, Chen S. Prediction of readmission in patients with acute exacerbation of chronic obstructive pulmonary disease within one year after treatment and discharge. BMC Pulmonary Medicine 2021;21(1) View
- Woo S, Alhaqqan D, Gildea D, Patel P, Cundra L, Lewis J. Highlights of the drug-induced liver injury literature for 2021. Expert Review of Gastroenterology & Hepatology 2022;16(8):767 View
- Zhuparris A, Maleki G, Koopmans I, Doll R, Voet N, Kraaij W, Cohen A, van Brummelen E, De Maeyer J, Groeneveld G. Smartphone and Wearable Sensors for the Estimation of Facioscapulohumeral Muscular Dystrophy Disease Severity: Cross-sectional Study. JMIR Formative Research 2023;7:e41178 View
- Ji S, Lu B, Pan X. A nomogram model to predict the risk of drug-induced liver injury in patients receiving anti-tuberculosis treatment. Frontiers in Pharmacology 2023;14 View
- Zhang F, Zhang F, Li L, Pang Y. Clinical Utilization of Artificial Intelligence in Predicting Therapeutic Efficacy in Pulmonary Tuberculosis. Journal of Infection and Public Health 2024 View
- Xiao Y, Chen Y, Huang R, Jiang F, Zhou J, Yang T. Interpretable machine learning in predicting drug-induced liver injury among tuberculosis patients: model development and validation study. BMC Medical Research Methodology 2024;24(1) View
- Lewis J, Korkmaz S, Rizk C, Copeland M. Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis. Expert Opinion on Drug Safety 2024;23(9):1093 View